22 Result(s)

Article

Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group

Daratumumab (DARA) is a human IgG-K monoclonal antibody (MoAb) targeting CD38 that is approved alone or in combination with bortezomib and dexamethasone or lenalidomide and dexamethasone for relapsed or refrac...

Federico Vozella, A. Siniscalchi, M. Rizzo, T. Za, G. Antolino… in Annals of Hematology (2021)

Article

Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma

A working group of six expert physicians convened to assess the spectrum of multiple myeloma relapse presentations, discussed the features that can define the disease as aggressive and not aggressive, and esta...

M. Offidani, M. Boccadoro, F. Di Raimondo… in Current Hematologic Malignancy Reports (2019)

Article

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma

This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide–dexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ⩾65 years ...

S Bringhen, M D'Agostino, L De Paoli, V Montefusco, A M Liberati, P Galieni… in Leukemia (2018)

Article

Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis

In newly diagnosed myeloma patients, upfront autologous transplant (ASCT) prolongs progression-free survival 1 (PFS1) compared with chemotherapy plus lenalidomide (CC+R). Salvage ASCT at first relapse may stil...

F Gay, S Oliva, M T Petrucci, V Montefusco, C Conticello, P Musto, L Catalano… in Leukemia (2017)

Article

An observational study assessing peripheral neuropathy related to multiple myeloma

We aimed at assessing the prevalence of peripheral neuropathy in newly diagnosed, treatment-naïve patients with multiple myeloma. We enrolled 153 patients with multiple myeloma at initial diagnosis. All patien...

C. Leone, V. Federico, S. La Cesa, E. Russo, G. Di Stefano… in Neurological Sciences (2016)

Article

A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma

This phase 2 trial evaluated three low-dose intensity subcutaneous bortezomib-based treatments in patients ⩾75 years with newly diagnosed multiple myeloma (MM). Patients received subcutaneous bortezomib plus o...

A Larocca, S Bringhen, M T Petrucci, S Oliva, A P Falcone, T Caravita… in Leukemia (2016)

Article

Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

M Cavo, L Pantani, A Pezzi, M T Petrucci, F Patriarca, F Di Raimondo… in Leukemia (2015)

Article

Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia

P Musto, V Simeon, M C Martorelli, M T Petrucci, N Cascavilla, F Di Raimondo… in Leukemia (2014)

Article

Peripheral nociceptor sensitization mediates allodynia in patients with distal symmetric polyneuropathy

Patients with painful neuropathy frequently complain of pain in response to normally non-painful brushing, namely dynamic mechanical allodynia. Despite many animal studies suggesting that allodynia arises when...

A. Truini, A. Biasiotta, G. Di Stefano, S. La Cesa, C. Leone… in Journal of Neurology (2013)

Article

Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy

Lenalidomide has raised concerns regarding its potential impact on the ability to collect stem cells for autologous stem cell transplantation, especially after prolonged exposure. The use of cyclophosphamide p...

F Cavallo, S Bringhen, G Milone, D Ben-Yehuda, A Nagler, E Calabrese… in Leukemia (2011)

Article

Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma

This multicenter, open-label, non-comparative phase II trial evaluated the safety and efficacy of salvage therapy with lenalidomide, melphalan, prednisone and thalidomide (RMPT) in patients with relapsed/refra...

A Palumbo, A Larocca, P Falco, G Sanpaolo, A P Falcone, V Federico, L Canepa… in Leukemia (2010)

Article

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

We present a pooled update of two large, multicenter MM-009 and MM-010 placebo-controlled randomized phase III trials that included 704 patients and assessed lenalidomide plus dexamethasone versus dexamethason...

M A Dimopoulos, C Chen, A Spencer, R Niesvizky, M Attal, E A Stadtmauer… in Leukemia (2009)

Article

High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias

The aim of the study was to evaluate the antileukemic effectiveness and toxicity of high-dose hydroxyurea (HHY) and to assess its acute toxicity. Between August 1997 and October 1998, 12 consecutive adult pati...

M. C. Petti, A. Tafuri, R. Latagliata, M. A. Aloe Spiriti… in Annals of Hematology (2003)

Article

Cell cycle regulation and induction of apoptosis by IL-6 variants on the multiple myeloma cell line XG-1

 Interleukin-6 (IL-6) serum levels and the proliferative activity of bone marrow plasma cells have been described as important prognostic factors for survival duration in multiple myeloma (MM) patients. Since ...

M. T. Petrucci, M. R. Ricciardi, C. Ariola, C. Gregorj… in Annals of Hematology (1999)